Search PubMed⌕ Search

Biomedical subjects

W Starkey

Publications and source records attributed to W Starkey.

5 recordsLinked to original sources

A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences.

Previously we reported the presence of a replication-competent retrovirus in supernatant from a vector-producing line derived from a widely used split-function amphotropic packaging cell line. Rigorous routine screening of all retroviral stocks produced in our laboratory has not, previously or since, indicated the presence of such a virus. Replication-competent retroviruses have never previously been used in our laboratory, and stringent screening of all routinely used cell lines has not revealed the presence of any helper viruses. Therefore, it is highly unlikely that this virus represents an adventitious cross-contaminant or had been imported unknowingly with our cell line stocks. PCR studies with DNA from infected cell lines and Northern blot analysis and reverse transcriptase PCR with RNA from infected cells suggest that the helper virus arose by recombination events, at sites of partial homology, between sequences in the vector, one of the packaging constructs, and endogenous retroviral elements. These recombinations were not present in stocks of the packaging cell line or in an initial stock of the vector-producing line, indicating that these events occurred while the vector-producing line was being passaged for harvest of supernatant stocks.

Animals↗

Recombinant rubella E1 fusion proteins for antibody screening and diagnosis.

BACKGROUND: Until rubella is eradicated there will be a continuing need for rubella antibody surveillance. Antigen production using recombinant DNA technology may be a viable alternative to traditional techniques of producing antigens for enzyme immunoassays (EIAs). OBJECTIVES: To investigate the potential of bacterial fusion proteins containing rubella E1 protein sequences for use in EIAs to detect rubella antibodies. STUDY DESIGN: Purified bacterial fusion proteins containing rubella E1 sequences to be used as antigens in EIAs and compared to 'traditional' assays using virus derived antigens for rubella antibody screening. RESULTS: cDNA clones coding for the complete rubella E1 protein sequence and subfragments of E1 were modified for expression as carboxy terminal fusions with either beta-galactosidase or glutathione-S-transferase. beta-galactosidase fusions with the complete E1 coding sequence or amino acids 201 to 307, which contain known epitopes, resulted in the production of predominantly insoluble fusion proteins unsuitable for use in EIA. Nine glutathione-S-transferase-E1 fusion proteins were produced with individual fusion proteins exhibiting varying properties with regard to the levels of protein produced, apparent stability, solubility and the potential for affinity purification using glutathione agarose. Reduction of the E1 component to only 44 amino acids containing three B-cell epitopes (Terry et al., 1988) produced an abundant soluble GST-E1 fusion protein (3.5 mug/ml), which could be affinity purified using glutathione agarose. This fusion protein has been successfully used in EIA to detect rubella antibodies. CONCLUSIONS: We have shown that GST-E1 fusions have potential as antigens in tests for rubella antibodies.

Journal Article↗

The ability of strains of Klebsiella aerogenes to survive on the hands.

The ability of Klebsiella aerogenes strains isolated from outbreaks of infection, from sporadic infections and from the environment to survive on hands were compared. Considered as groups, the outbreak strains survived best and the environmental strains least well. The possible importance of these observations in relation to outbreaks of Klebsiella infection in hospitals and to heterogeneity of pathogenic potential and transmissibility in Klebsiella aerogenes is discussed.

Disease Outbreaks↗